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Abstract
Purpose Patients with a neuroendocrine tumor (NET) fre-
quently experience physical and psychosocial complaints.
Novel strategies to provide information to optimize supportive
care in these patients are of interest. The aim of this study was
to examine whether the use of a web-based system consisting
of self-screening of problems and care needs, patient educa-
tion, and self-referral to professional health care is feasible in
NET patients and to evaluate their opinion on this.
Methods Newly diagnosed NET patients were randomized
between standard care (n = 10) or intervention with additional
access to the web-based system (n = 10) during 12 weeks.
Patients completed questionnaires regarding received infor-
mation, distress, quality of life (QoL), and empowerment.
The intervention group completed a semi-structured interview
to assess patients’ opinion on the web-based system.
Results The participation rate was 77% (20/26 invited pa-
tients) with no dropouts. The use of the web-based system
had a negative effect on patients’ perception and satisfaction
of received information (range Cohen’s d −0.88 to 0.13).
Positive effects were found for distress (Cohen’s d 0.75), glob-
al QoL (subscale European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30, Cohen’s d 0.46),
resolving problems with social functioning and finding infor-
mation (subscales EORTC QLQ-GINET 21, Cohen’s d 0.69,
respectively, 1.04), and feeling informed (subscale empower-
ment questionnaire, Cohen’s d 0.51). The interview indicated
that the web-based system was of additional value to standard
care.
Conclusions Use of this web-based system is feasible.
Contradictory effects on informing and supporting NET pa-
tients were found and should be subject of further research.
Trial registration NCT01849523
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Introduction
Neuroendocrine tumors (NETs) are rare tumors arising
from secretory cells of the neuroendocrine system.
Secretion of hormones and/or amines can result in a broad
set of symptoms [1, 2]. Patients can experience various
symptoms as a consequence of the presence of the tumor
as well as the release of the hormones secreted by the
tumor. Also, side effects of the treatment can bother them.
Moreover, diagnosis and treatment of cancer often results
in physical, psychological, practical, social, and spiritual
concerns [3]. Studies in patients with NETs demonstrate
that these concerns lead to lower health-related quality of
life (QoL) compared with the general population [4, 5]. In
general, when patients with cancer are properly informed,
they experience a better health-related QoL and less de-
pression and anxiety [6, 7]. In addition, providing informa-
tion also results in an increased participation of patients in
decision-making, greater satisfaction with care, lower
levels of distress, and improved sense of control [7–10].
Among patients with cancer, the increasing role of in-
ternet as a source of cancer-related information is
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recognized. Web-based patient education and support have
become widely accepted [11–13]. We developed a web-
based system for NET patients with the aim to examine
its feasibility and to evaluate patient’s opinion on this.
Secondary aims were to explore the effects on patients’
perception and satisfaction of received information, dis-
tress, health-related QoL, and empowerment. The web-
based system allows patients to self-screen for physical
and psychosocial problems, to get tailored patient educa-




To be eligible for this study, patients had to be newly diag-
nosed with a NET grade 1 or 2 (according to the World
Health Organization 2010 classification) within 3 months
before study participation. Any primary site or disease
stage was allowed. Patients had to be under surveillance
or treatment at the Department of Medical Oncology in
the University Medical Center Groningen (UMCG).
Additional inclusion criteria were 18 years of age or older
and ability to read and write Dutch. Not eligible were pa-
tients with an estimated life expectancy of less than
3 months or a second primary tumor with active follow-
up or treatment. All eligible patients were invited to partic-
ipate. Recruitment occurred at the outpatient clinic during
October 2013 to January 2014. The study was approved by
the medical ethical committee of the UMCG and registered
in ClinicalTrials.gov (NCT01849523). All patients gave
written informed consent.
Study procedure
For detailed description of study procedures, see Appendix
1. Eligible patients were informed about the study by their
treating medical oncologist during a follow-up visit or by
phone if a follow-up visit was not planned at short notice.
Patients were asked if they could be approached for study
participation by one of the investigators. If this was
allowed, the investigator informed the patient orally after
the follow-up visit or by phone. Patients were informed
about the aims, study procedures, and feasibility design
of this study. Following obtained informed consent, pa-
tients were randomized in a 1:1 ratio to the standard care
group or the intervention group that received standard care
with additional access to the web-based system. At base-
line, all patients received questionnaires by mail regarding
socio-demographic characteristics, health care/internet use,
perception and satisfaction of received information
(EORTC QLQ-INFO25), and QoL (EORTC QLQ-C30,
EORTC QLQ-GINET21). At baseline, the standard care
group received the paper-and-pencil version of the distress
thermometer (DT) and problem list (PL) by mail. The in-
tervention group had to complete the online version of the
DT and PL (content identical to the paper-and-pencil ver-
sion). When questionnaires were completed, the interven-
tion group received instructions how to use the web-based
system together with log-in information including a per-
sonal username and password. At week 12, all patients
received questionnaires by mail regarding frequency of
visits to psychosocial and/or allied health care profes-
sionals, perception and satisfaction of received informa-
tion, QoL, and empowerment (Constructs Empowering
Outcomes, CEO questionnaire). The standard care group
also received the paper-and-pencil version of the DT and
PL by mail. The intervention group was reminded to com-
plete the online version of the DT and PL after 12 weeks.
At end of the study, the patients assigned to the interven-
tion group were also invited for a semi-structured interview
with the investigator regarding their opinion on the web-
based system.
Randomization outcome was not blinded and also notified
to the treating medical oncologist. In this manner, all patients
could discuss their questions about the retrieved information
(e.g., from the web-based system, information leaflets) with
their treating medical oncologist, oncology nurse, other health
care professionals, and/or allied health care workers.
Standard care and study intervention
Standard care for newly diagnosed patients with a NET
during the first visit(s) at the Department of Medical
Oncology includes verbal information about the diagnosis,
evaluating complaints/problems and a physical examina-
tion by their treating medical oncologist. Also, newly di-
agnosed patients visit an oncology nurse with experience
in care for NET patients. All patients receive at diagnosis
information leaflets of the Dutch Patient Neuroendocrine
Tumor Foundation [14]. During follow-up visits, the med-
ical oncologist evaluates and discusses the general well-
being, test results, treatment (e.g., options, side effects),
answers questions of the patient, and performs a physical
examination. If physical and/or psychosocial problems re-
quire more in-depth discussion, investigation or treatment,
patients can receive a consultation with the oncology nurse
or other health care professionals.
In the intervention group, patients received access to
the web-based information and support system in addition
to standard care during the 12-week study period. The
web-based system incorporates elements of self-
screening for problems and care needs, tailored support
in self-help, patient education, and communication with
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a health care professional. Patients screened themselves
for psychosocial/physical problems and care needs by fill-
ing out the DT and PL. Immediately after completion of
the DT, automated personalized feedback was received
upon their reported distress score. For example, feedback
emphasizes the possibility for a referral to a health care
professional for moderate or severe distress. Thereafter,
patients received tailored feedback on physical/
psychosocial problems they had reported on the PL.
This feedback comprises background information about
the problem, advice on how to cope with the problem
(Bself-help advice^) and which health care professional
can be consulted when self-help insufficiently alleviates
problems. Online completed DT and PL questionnaires
with feedback were online saved and coded to ensure that
patients could access the feedback and information later.
Also, general information about NETs and diagnostic pro-
cedures, treatments, and their side effects is provided by the
web-based system. Patients could send an e-mail or request
for a telephone call to communicate with the investigator (ex-
perienced physician in treating NET patients) in case of ques-
tions, problems, or a referral wish. A referral wish to a profes-
sional or allied health care worker was arranged by the treating
medical oncologist.
Measures
Patient characteristics including socio-demographic char-
acteristics, use of previous and current psychosocial and/
or allied health care, acquaintance with internet, and use
of internet to search cancer-related information were
assessed by a self-report questionnaire. Information on
disease-related characteristics was collected from medical
records.
Participation and dropout rates and reasons for declining
study participation and dropout were tracked.
Patients’ perceived amount and satisfaction of received
information was measured with the Dutch EORTC QLQ-
INFO25 questionnaire, which is a validated questionnaire
to evaluate the information received by cancer patients
[15]. This questionnaire comprises multi-items grouped
into four information provision subscales Bperceived re-
ceipt of information about the disease,^ Bmedical tests,^
Btreatment^ and Bother care services^ and single items on
Bhaving received information^ in different manners (e.g.,
written, online, on CD) and on Bsatisfaction with, amount
of and helpfulness of information.^ In addition, two open
questions investigate topics of which patients would like
to receive more or less information. All responses are
ranged on a 4-point Likert scale, except for four single
items that have a Byes/no^ scale.
Distress was measured using the validated Dutch DT
and PL [3]. The DT consists of a single item asking
patients to indicate the amount of overall distress experi-
enced during the past week on an 11-point scale (range B0^
no distress–B10^ extreme distress). The PL identifies
existing practical, family/social, emotional, religious/spiri-
tual, and physical problems and was adapted by the inves-
tigators according to the issues which are prevalent among
and relevant to patients with NETs (in total 31 items).
Patients could also add a problem that was not mentioned
in the PL. For each reported problem, patients rated the
associated experienced amount of distress (range B0^ no
distress–B10^ extreme distress). The PL ends with the
question whether the patient has a referral wish to an on-
cology nurse, peer NET sufferer group, a psychosocial
(psychologist, social or pastoral worker), or allied health
care professional (e.g., physical therapist, dietician).
QoL was measured with the validated Dutch EORTC
QLQ-C30 (version 3) [16] and Dutch EORTC QLQ-
GINET21 [17]. The EORTC QLQ-C30 measures cancer-
specific QoL comprising five functional scales (physical,
role, cognitive, emotional, and social), three symptom
scales (fatigue, pain and nausea/vomiting), six single
symptom items (dyspnea, insomnia, loss of appetite, con-
stipation, diarrhea, and financial impact), and a global
health status/QoL scale. Responses are given on a 4-
point Likert scale (range B1^ not at all–B4^ very much)
with higher scores indicating higher QoL at the functional
scales and higher symptom burden for the symptom
scales. The global health status/QoL scale is scored on a
7-point scale (range B1^ very poor–B7^ excellent) with
higher scores indicating higher QoL. The EORTC QLQ-
GINET21 is a disease-specific QoL questionnaire for pa-
tients with a gastrointestinal NET to supplement the
EORTC QLQ-C30 questionnaire and assesses specific
disease symptoms, side effects of treatment, body image,
disease-related worries, social functioning, communica-
tion, and sexuality. Responses are given on a 4-point
Likert scale (range B1^ not at all–B4^ very much) with
higher scores indicating higher symptom burden for the
symptom scales.
Empowerment was measured by the Dutch CEO ques-
tionnaire, which is developed and tested in different on-
line support groups including breast cancer patients [11,
18]. In the questionnaire, Bonline support groups^ was
modified in Bwebsite^ for the intervention group and in
Bstandard care^ for the control group. The domains Bbeing
better informed,^ Bfeeling more confident about the rela-
tionship with their physician,^ Bimproved acceptance of
the illness,^ Bfeeling more confident about the treatment,^
and Bincreased optimism and control over the future^
were measured since these domains were expected to be
influenced by the web-based system.
Patients’ opinion regarding satisfaction with the web-
based system was assessed with a semi-structured
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interview by phone with participants in the intervention
group. Ten open-ended, both qualitative and quantitative
questions were used and when relevant the interviewer
probed the participant with follow-up questions to include
topics not established beforehand. These questions com-
prised the following issues: contents, lay out, user-friend-
liness, perceived usability, usage and future recommenda-
tions. The interviews were recorded and afterwards all
interviews were transcribed in English. All topics per in-
dividual interview related to the purpose of the research
were noted and categorized.
Statistical analysis
The purpose of this study was to explore the feasibility and
to evaluate patient’s opinion on the web-based system on
abovementioned endpoints. Twenty NET patients were re-
cruited and randomized. Descriptive statistics (e.g., means,
ranges, frequencies) were calculated for all measures.
Missing values for the EORTC questionnaires were han-
dled according to the EORTC guidelines [19]. Raw scores
of all scales and items of the EORTC questionnaires were
linearly transformed to a score ranging from 0 to 100 [19].
Scores of the different problem/empowerment domains of
the PL/CEO questionnaire were calculated by taking the
mean of the total scores of the items in each domain.
Effect sizes for change scores on each endpoint were de-
termined (Cohen’s d) by using the mean difference be-
tween post- and pre-intervention scores of both groups
and dividing this difference by the pooled standard devia-
tion. Given the retrospective design of the CEO question-
naire with only a post-intervention measurement, effect
sizes of the outcomes of the CEO were calculated by using
the mean difference between post-intervention scores of
both groups and dividing this difference by the accompa-
nying pooled standard deviation.
All effect sizes are reported so that a positive effect size
indicates a desired direction (i.e., improvement of outcome in
favor of the intervention group). An effect size (ES) between
0.20–0.50 is defined as small, between 0.50 and 0.80 as me-
dium and ≥0.80 as large. Analyses were performed using the




Twenty of the 26 invited eligible patients gave informed
consent and all patients completed the full study period.
Reasons for declining study participation were no access
to a computer and internet (n = 2), no interest in
information and filling out questionnaires (n = 1), feeling
overburdened (n = 2) and not willing to be further
confronted with the disease (n = 1).
Patient and tumor characteristics are summarized in
Table 1. There was a minor imbalance between the in-
tervention and control group regarding age, educational
level and primary tumor localization. The intervention
group consisted of younger, higher educated patients
and more patients with a NET of the lung. During the
study, six patients (n = 1 in the standard care group)
started treatment with a somatostatin analog and two pa-
tients (both in standard care group) with everolimus.
Three patients (n = 1 in the standard care group)
underwent curative surgery and two patients in the inter-
vention group underwent palliative surgery during the
study period.
Effect of intervention on outcomes
In the standard care group, one patient was supported by a
social worker and another patient by a psychologist during
the study period. In the intervention group, two patients re-
ceived treatment of a physical therapist (n = 2) and/or dietician
(n = 1).
Table 2 presents mean scores of the different subscales of
EORTC QLQ-INFO25 at baseline and end of study for the
two groups and the accompanying effect sizes. Most out-
comes on subscales showed negative effect sizes indicating
that the intervention group had less improvement in feeling
informed. None of the patients wished to receive less infor-
mation. At baseline, less patients in the intervention group
wished to receive more information (50 vs. 70% in the inter-
vention respectively standard group).
Baseline and end of study mean scores and accompa-
nying effect sizes of the DT and PL are summarized in
Table 3. A medium ES was observed for distress and
social problems in favor of the intervention group.
Trivial or small effect sizes were observed for problems
in the other domains. Few patients experienced religious/
spiritual problems.
Outcomes for QoL measured by EORTC QLQ-C30 and
EORTC QLQ-GINET21 questionnaires are depicted in
Tables 4 and 5. The intervention group showed a higher in-
crease in QoL (small ES). A moderate ES was observed for
cognitive functioning in favor of the standard care group. In
contrast, financial difficulties and pain improved more (mod-
erate effect sizes) in the intervention group.
The intervention group showed more improvement on
disease-specific problems measured by the EORTC QLQ-
GINET21 questionnaire. For example, large effect sizes were
observed for disease-related worries.
Outcomes of the different domains of empowerment are
presented in Table 6. The intervention group felt better
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informed (moderate ES) and had more confidence in their
treatment (small ES). In contrast, the standard care group
scored higher for the domain Bacceptance of illness^ (small
ES) and Boptimism and control over the future^ (moderate
ES).
Qualitative and quantitative semi-structured interview
To evaluate patient’s opinion on the web-based system, all
patients in the intervention group were interviewed.
The number of times the web-based system was visited
ranged from 2–5 (n = 4 patients), 6–10 (n = 2), 11–15 (n = 3)
to 16–20 (n = 1). Frequently visited parts of the web-based
system were Bdiagnostic procedures^ and Btreatments.^ The
DT, specific information about NET, and the part on Bdiagnostic
procedures^ and Btreatments^ were found most useful.
All patients found the web-based system user-friendly.
All but one patient found the information presented by the
web-based system understandable. Most patients (n = 6)
found the provided information by the web-based system
Bpretty complete,^ Bcomplete,^ or Bvery complete.^
Suggestions for information to add to the web-based system
were Bfrequently used medications in NET patients other than
tumor treatments (e.g., laxatives),^ Badvice about healthy life
style,^ and Blife expectancy.^
Seven patients preferred information on their type of tumor
only. Two patients were also interested in other types of tu-
mors and enjoyed reading about it.
Table 1 Patient and tumor
characteristics Standard care group (n = 10) N
a Intervention group (n = 10) Na
Median age in years (range) 64.0 (45–74) 59.5 (41–74)
Gender M/F 5/5 4/6
Educational level
Lower vocational education 6 3
Intermediate vocational education 3 5





In daily life 8 9






Disease stage (according to UICCb)
Stage I/II 0 2
Stage III 1 2
Stage IV 9 6
Treatment prior to study participation (%) 80% 50%
Somatostatin analog 6 4
Curative surgery 0 1
Palliative surgery 4 2
Everolimus 0 1
Radiofrequency ablation 1 0
Otherc 1 0
Health care use before diagnosis (%) 20% 10%
Physical therapist 1 1
Psychologist 1 0
a Data are expressed as number unless noted otherwise
b Union for International Cancer Control
c Proton pump inhibitor
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Most patients (n = 8) found the web-based system of
additional value. All would recommend this web-based
system to peers and believed this should be part of the
standard care. Also, several patients considered it of in-
terest for people surrounding the NET patient (e.g., fam-
ily, friends, general practitioners). All wanted to use the
web-based system in the future. Patients would like to use
it immediately upon diagnosis.
Discussion
This is the first study examining whether use of a web-based
information and support system is feasible in NET patients.
The results suggest that use of this web-based system is
feasible. The NET patients appreciated the use of the web-
based system and found its use of additional value to standard
care. This exploratory study was not powered to detect differ-
ences between the two groups.
Use of eHealth-tools is increasing and a goal of the
European Commission to improve citizens’ health [20].
Given the lack of available eHealth-tools in NET patients,
there is an unmet need for a professionally designed web-
based information and support system in these patients. Our
results provide information to further develop web-based in-
formation systems in rare cancer types like NET.
Patients using the web-based information system had
less problems with finding adequate information and felt
better informed as measured by the EORTC QLQ-
GINET21 and CEO. Unexpectedly, the results of the
Table 2 Perceived information
and satisfaction (EORTC QLQ-
INFO25)
Standard care group (n = 10) Intervention group (n = 10)
Outcome Pre M (SD) Post M (SD) Pre M (SD) Post M (SD) ES
Information about:
Disease 33.33 (21.52) 42.50 (18.19) 35.83 (21.89) 39.17 (19.66) −0.30
Medical tests 48.89 (21.72) 56.67 (16.93) 57.78 (15.54) 61.11 (22.38) −0.22
Treatments 32.78 (13.21) 44.44 (15.27) 29.44 (17.77) 33.33 (16.56) −0.59
Other services 12.50 (14.83) 30.00 (30.73) 10.83 (15.24) 14.17 (16.22) −0.74
Different places of care 16.67 (28.32) 23.33 (31.62) 16.67 (28.33) 13.33 (28.11) −0.17
How to help yourself 13.33 (23.31) 33.33 (31.43) 20.00 (23.31) 20.00 (28.11) −0.88
Received written information 80.00 (42.16) 80.00 (42.16) 100.00 (0.00) 70.00 (48.30) −0.52
Received CD/video 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00
Satisfaction with information 46.67 (23.31) 50.00 (23.57) 50.00 (23.57) 56.67 (22.50) 0.13
Wanting to receive more info 30.00 (48.30) 60.00 (51.64) 50.00 (52.70) 60.00 (51.64) −0.28
Wanting to receive less info 100.00 (0.00) 100.00 (0.00) 100.00 (0.00) 100.00 (0.00) 0.00
Helpfullness of information 46.67 (17.21) 56.67 (22.50) 46.67 (17.21) 56.67 (27.44) 0.00
Global score 38.40 (13.30) 48.08 (12.82) 43.10 (10.51) 43.70 (13.66) −1.06
Higher scores mean more/better information and satisfaction
Pre M mean score at baseline, Post M mean score at 12 weeks, SD standard deviation, ES effect size
Table 3 Distress (distress
thermometer and problem list) Standard care group (n = 10) Intervention group (n = 10)
Outcome Pre M (SD) Post M (SD) Pre M (SD) Post M (SD) ES
Distress level 4.90 (2.96) 4.60 (3.03) 4.10 (3.32) 2.00 (1.49) 0.75
Problems
Practical 5.10 (6.42) 5.60 (6.79) 8.20 (13.30) 7.80 (12.75) 0.16
Social 0.20 (0.63) 0.90 (2.03) 2.60 (5.23) 2.00 (3.27) 0.53
Emotional 17.00 (22.40) 12.50 (14.65) 20.10 (19.20) 12.20 (14.40) 0.20
Spiritual 0.00 (0.00) 0.00 (0.00) 0.50 (1.58) 0.40 (0.97) 0.19
Physical 18.10 (11.83) 11.80 (10.62) 16.90 (11.40) 11.70 (11.41) −0.10
Global score 40.40 (34.63) 30.80 (27.12) 48.30 (43.33) 34.10 (39.86) 0.18
Higher scores mean more distress/problems
Pre M mean score at baseline, Post M mean score at 12 weeks, SD standard deviation, ES effect size
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EORTC QLQ-INFO25 demonstrated that use of the web-
based system resulted in less improvement of feeling in-
formed and satisfaction of received information. The
EORTC QLQ-INFO25 is not specifically developed for
patients with an NET, which could potentially explain the
observed difference between questionnaires. However, it is
possible that a web-based system results in feeling worse
informed and more depressed. In contrast to face-to-face
contact with health care providers, visiting a web-based
system does not offer the possibility to discuss feelings of
insecurity in person or to ask questions after having read
disturbing information about their disease. Also, the inter-
vention group had less acceptance of illness and less con-
trol and optimism regarding the future at the end of the
Table 4 Quality of life (EORTC
QLQ-C30) Standard care group (n = 10) Intervention group (n = 10)
Outcome Pre M (SD) Post M (SD) Pre M (SD) Post M (SD) ES
Global quality of life 59.17 (20.95) 58.33 (24.53) 65.83 (26.77) 70.83 (17.67) 0.46
Functioning
Physical 73.33 (23.09) 76.67 (24.19) 79.33 (27.30) 80.67 (20.23) −0.15
Role 61.67 (28.38) 61.67 (32.44) 66.67 (36.00) 70.00 (21.94) 0.15
Emotional 67.50 (36.74) 73.33 (25.99) 70.00 (32.20) 78.33 (20.11) 0.11
Cognitive 78.33 (27.27) 83.33 (24.85) 78.33 (20.86) 70.00 (23.31) −0.61
Social 68.33 (14.59) 75.00 (26.35) 73.33 (31.62) 78.33 (20.86) −0.08
Symptoms
Dyspnea 23.33 (27.44) 20.00 (23.31) 36.67 (33.15) 30.00 (24.60) 0.15
Insomnia 16.67 (23.57) 20.00 (28.11) 23.33 (27.44) 20.00 (28.11) 0.21
Appetite loss 23.33 (35.31) 10.00 (22.50) 20.00 (35.83) 13.33 (23.31) −0.30
Constipation 6.67 (14.05) 10.00 (22.50) 16.67 (32.39) 13.33 (23.31) 0.14
Diarrhea 23.33 (22.50) 23.33 (38.65) 16.67 (32.39) 16.67 (32.39) 0.00
Financial difficulties 10.00 (16.10) 23.33 (27.44) 26.67 (43.89) 23.33 (35.31) 0.63
Fatigue 45.56 (31.62) 37.78 (34.03) 33.33 (36.29) 33.33 (28.21) −0.40
Nausea and vomiting 13.33 (20.49) 1.67 (5.27) 18.33 (33.75) 10.00 (21.08) −0.12
Pain 26.67 (33.52) 25.00 (26.35) 35.00 (38.05) 21.67 (20.86) 0.52
Higher scores for quality of life and functioning represent higher quality of life and level of functioning. Higher
scores for symptoms represent a higher level of symptomatology
Pre M mean score at baseline, Post M mean score at 12 weeks, SD standard deviation, ES effect size
Table 5 Quality of life (EORTC QLQ-GINET21)
Standard care group (n = 10) Intervention group (n = 10)
Outcome Pre M (SD) N Post M (SD) N Pre M (SD) N Post M (SD) N ES
Endocrine symptoms 27.78 (19.07) 10 22.22 (14.81) 10 25.56 (21.63) 10 13.33 (11.48) 10 0.35
Gastrointestinal symptoms 28.00 (22.40) 10 27.33 (14.55) 10 30.67 (29.18) 10 24.00 (21.36) 10 0.34
Treatment-related symptoms 14.44 (18.22) 5 15.54 (18.56) 5 14.44 (18.22) 5 23.33 (16.81) 5 −0.40
Problems social functioning 28.89 (15.89) 10 35.56 (12.62) 10 42.22 (28.11) 10 38.89 (24.15) 10 0.69
Disease-related worries 33.95 (26.42) 9 42.59 (31.18) 9 45.00 (28.50) 10 32.22 (22.03) 10 0.92
Pain muscles/bone 16.67 (23.57) 10 16.67 (23.57) 10 37.50 (45.21) 8 37.50 (33.03) 8 0.00
Problems sexual functioning 9.52 (16.27) 7 14.29 (26.23) 7 38.89 (38.97) 6 33.33 (42.16) 6 0.52
Problems receiving information 13.33 (17.21) 10 20.00 (23.31) 10 23.33 (27.44) 10 10.00 (16.10) 10 1.04
Problems body image 20.00 (17.21) 10 13.33 (17.21) 10 3.33 (10.54) 10 6.67 (14.05) 10 −0.60
Higher scores mean more or worse symptoms/problems
Pre M mean score at baseline, N number of patients, Post M mean score at 12 weeks, SD standard deviation, ES effect size
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study period. A randomized controlled study examining
different types of internet support groups in breast cancer
patients, also reported negative effects on depression and
anxiety in the internet support patients who received addi-
tional information and support of other breast cancer pa-
tients [21]. Being provided with more information can pos-
sibly be confronting for patients with cancer which may
result in an increase of negative thoughts and worse future
perspectives.
This study had a small sample size due to the feasibility
design. Younger age and higher educational level are associ-
ated with more internet use for health care information [22].
Therefore, the intervention groupmay have had amore critical
view on the received information. As a result of these small
sample sizes despite randomization, the intervention group
was younger, higher educated and comprised three lung
NET patients. The DT/PL is an element of the web-based
system and therefore the intervention group had to fill out
the DT/PL online instead of a paper-and-pencil version.
Since the content of the online DT/PL is identical to the
paper-and-pencil version, we do not expect that this has af-
fected the outcome.
The results of the current study have given insight
into the existing worries and problems of NET patients,
but also into the needs and expectations of information
and support. This has enabled us to develop a sufficient-
ly powered randomized controlled trial investigating an
adapted web-based system for patients with both new
and a longer known diagnosis of NET (ClinicalTrials.
gov Identifier NCT02472678). Mainly based on the
results of the semi-structured interview, adaptations have
been made to the web-based system, such as adding new
information (e.g., information about commonly used
medication by NET patients and average life expectan-
cy), Btruths and hoaxes^ about NET, and experiences of
patients with different types of NET with their disease.
Hopefully, firm conclusions about effects of this web-
based system can be drawn after finishing this study. If
the web-based system is proven effective after finishing
this study, it will become available for all NET patients
in the Netherlands.
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Appendix 1. Extensive description study procedures
Eligible patients were informed by their treating medical on-
cologist about the study during a follow-up visit or by phone if
the next follow-up visit was planned beyond 2 months.
Patients who were interested in study participation were sub-
sequently approached by one of the investigators and received
study information. Following informed consent, patients were
randomized in a 1:1 ratio to standard care group or the inter-
vention group that received standard care with additional ac-
cess to the web-based system. Randomization was performed
by e-mail from the investigator to the central data manager of
the Department of Medical Oncology (UMCG) who is not
involved in the recruitment or treatment of the patients. For
allocation to the standard care or intervention group, a
computer-generated randomization list was used. The alloca-
tion sequence was concealed from the investigator. The inves-
tigator was informed by e-mail to which group the patient was
assigned. The investigator informed the patient by phone
about the randomization outcome and further process. Also,
the treatingmedical oncologist was notified about the random-
ization outcome. After randomization, all patients received
questionnaires by mail about socio-demographic characteris-
tics, health care/internet use, perception and satisfaction of
received information (EORTC QLQ-INFO25), and quality
of life (EORTC QLQ-C30, EORTC QLQ-GINET21) as base-
line measurement. The standard care group also received the
paper-and-pencil version of the distress thermometer (DT) and
problem list (PL). After the investigator had collected these
completed questionnaires, the intervention group received via
Table 6 Empowerment (CEO)
Standard care group (n = 10) Intervention group (n = 10)
Outcome Mean (SD) Mean (SD) ES
Feeling informed 13.60 (3.86) 15.30 (3.02) 0.51
Confidence in relationship physician 37.06 (6.78) 36.20 (10.17) −0.10
Confidence in treatment 16.60 (4.35) 18.60 (4.30) 0.46
Acceptance of illness 17.60 (2.12) 16.40 (5.54) −0.29
Optimism and control over future 25.00 (4.69) 22.50 (3.87) −0.58
Higher scores represent better empowerment for each outcome
Mean mean score (at 12 weeks), SD standard deviation, ES effect size
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their preferred route an e-mail or letter with a short introduc-
tion of the web-based system together with log-in information
including a personal username and password. These patients
were asked to complete the online DT and PL within 1 week
after having received the log-in information (baseline measure
DT and PL). At week 12, all patients received questionnaires
by mail about health care use, perception and satisfaction of
received information, quality of life, and empowerment
(Constructs Empowering Outcomes questionnaire) as end of
study measurement. The standard care group also received the
paper-and-pencil version of the DT and PL. The intervention
group was reminded by an e-mail/letter to complete the online
version of the DT and PL after 12 weeks. Patients assigned to
the intervention group were also requested to complete a semi-
structured interview regarding their opinion on the web-based
system by phone.
Open Access This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits any noncom-
mercial use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons license, and indicate if changes were
made.
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